|Day Low/High||158.03 / 160.05|
|52 Wk Low/High||130.09 / 181.81|
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Study met Primary Endpoint of Non-Inferiority Versus Zoledronic Acid in Delaying Bone Complications Known as Skeletal-Related Events
AMGN is neutral now, but a close below $158 weakens the chart picture.
Both it and Ligand Pharmaceuticals look significantly undervalued relative to their prospects.
Results From Exploratory Pooled Phase 1 and 2 Analysis Show BLINCYTO, the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S., Induced Complete Remission in Some Patients in all Pre-specified Subgroups
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Stock losses accelerate on Thursday as Deutsche Bank and Wells Fargo drag on the financials sector.
Pivotal ARISE Study of Erenumab in Episodic Migraine Prevention Met Primary Endpoint
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
U.S. stocks climbed and the Dow Jones Industrial Average jumped more than 100 points thanks to gains in the tech and consumer sectors.
Stocks add to gains in a relief rally Tuesday following the the first of three presidential debates on Monday.
Amgen announced today (AMGN) that its Phase III trial for Kyprolis, a plasma cell cancer drug, produced results that were not statistically significant.
Stocks move higher in a relief rally Tuesday following the the first of three presidential debates on Monday.
Stock futures creep higher on Tuesday following the first of three presidential debates, though a drop in crude oil caps gains.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Amgen to Hold Analyst Call Today at 8:30 a.m. ET
Opportunity for Life Sciences and Biotech Startups to Submit Proposal to Win Golden Ticket
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
First Regulatory Approval for Company's Biosimilar Portfolio
The FDA approved Amgen's (AMGN) generic version of AbbVie's (ABBV) Humira drug.
UnitedHealth becomes the second major healthcare provider to scratch the insulin product from its 2017 medicines roster.